Mealey's (October 17, 2016, 12:24 PM EDT) -- BOSTON — A pharmaceutical company and certain of its executive officers and directors and others misrepresented the success of clinical test results for the company’s prostate cancer drug in violation of federal securities laws, investors argue in a Sept. 29 complaint (Michael Garbowski, et al. v. Tokai Pharmaceuticals Inc., et al., No. 16-11963, D. Mass.)....